Heinz, Amadeus T. and Calkoen, Friso G. J. and Derbich, Alexander and Miltner, Lea and Seitz, Christian and Doering, Michaela and Braun, Christiane and Atar, Daniel and Schumm, Michael and Heubach, Florian and Arendt, Anne- Marie and Schulz, Ansgar and Schuster, Friedhelm R. and Meisel, Roland and Strahm, Brigitte and Finke, Juergen and Heineking, Beatrice and Stetter, Susanne and Silling, Gerda and Stachel, Daniel and Gruhn, Bernd and Debatin, Klaus-Michael and Foell, Juergen and Schulte, Johannes H. and Woessmann, Wilhelm and Mauz-Koerholz, Christine and Tischer, Johanna and Feuchtinger, Tobias and Handgretinger, Rupert and Lang, Peter (2023) Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation. HAEMATOLOGICA, 108 (8). pp. 2080-2090. ISSN 0390-6078, 1592-8721
Full text not available from this repository. (Request a copy)Abstract
Therapy-resistant viral reactivations contribute significantly to mortality after hematopoietic stem cell transplantation. Adoptive cellular therapy with virus-specific T cells (VST) has shown efficacy in various single-center trials. However, the scalability of this therapy is hampered by laborious production methods. In this study we describe the in-house production of VST in a closed system (CliniMACS Prodigy & REG; system, Miltenyi Biotec). In addition, we report the efficacy in 26 patients with viral disease following hematopoietic stem cell transplantation in a retrospective analysis (adenovirus, n=7; cytomegalovirus, n=8; Epstein-Barr virus, n=4; multi-viral, n=7). The production of VST was successful in 100% of cases. The safety profile of VST therapy was favorable (n=2 grade 3 and n=1 grade 4 adverse events; all three were reversible). A response was seen in 20 of 26 patients (77%). Responding patients had a significantly better overall survival than patients who did not respond (P<0.001). Virus-specific symptoms were reduced or resolved in 47% of patients. The overall survival of the whole cohort was 28% after 6 months. This study shows the feasibility of automated VST production and safety of application. The scalability of the CliniMACS Prodigy & REG; device increases the accessibility of VST treatment.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | EPSTEIN-BARR-VIRUS; ADOPTIVE TRANSFER; LYMPHOPROLIFERATIVE DISEASE; ADENOVIRUS INFECTIONS; 3RD-PARTY DONORS; CYTOMEGALOVIRUS; EBV; IMMUNITY; GANCICLOVIR; PROPHYLAXIS; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) Medicine > Lehrstuhl für Kinder- und Jugendmedizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 09 Apr 2024 12:47 |
| Last Modified: | 09 Apr 2024 12:47 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60505 |
Actions (login required)
 |
View Item |
